Business Wire

GENERATE-CAPITAL

17.7.2024 09:01:34 CEST | Business Wire | Press release

Share
GrowUp, the UK’s best-selling vertical farm, receives £38 million investment from Generate Capital to produce locally grown, pesticide-free greens

Today, Generate Capital, a leading sustainable infrastructure investment and operating company, and GrowUp, the UK’s best-selling vertical farm, announced a £38 million investment to meet growing demand for GrowUp’s popular ready-to-eat salads.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717534198/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Unbeleafable zesty baby leaves are the latest ready-to-eat bagged salad from GrowUp, which launched in Tesco stores in May. This is the only bagged salad available in the UK that provides the unique mix of sorrel leaves and green and red baby lettuce leaves, which have been grown in GrowUp's vertical farm in Kent. (Photo: Business Wire)

Generate Capital’s investment will help expand capacity at GrowUp’s Kent vertical farm, accelerate GrowUp's leadership of the UK salad category, support the Unbeleafable and Fresh Leaf Co. brands, drive R&D at GrowUp’s Leaf Lab site in Cambridge, and increase GrowUp's influence as a certified B Corp.

This funding extends Generate Capital's existing partnership with GrowUp, following an initial financing in 2021 that enabled GrowUp to prove its energy-efficient growing system and start converting a five-acre brownfield site into the equivalent of 1,000 acres of grade 1 farmland in Kent. GrowUp is the first vertical farm to have supplied branded, bagged salads to the country’s largest supermarket chain, Tesco, and to Iceland, SPAR, as well as other major food service customers.

“This investment is a fantastic boost to GrowUp and recognises the team’s passion and talent. We partnered with Generate Capital because, as a $10 billion sustainable infrastructure investor with a mission to ‘rebuild the world together’, Generate Capital aligns with our ethos. With Generate Capital's support, we have proved that vertically farmed salads are sustainable, cost competitive, and commercially viable, as well as tasty, healthy and long lasting. Together we can unlock a new salad category and meet growing consumer demand,” said Marcus Whately, CEO of GrowUp.

“Consumers want UK-grown, sustainable, longer-lasting leaves – grown without pesticides. With this further investment, we can expand production to meet demand and continue to transform UK food production. We've been growing for over 11 years now. We've come a long way with Generate Capital's support, since Kate Hofman and Tom Webster set up their first vertical farm in 2013, supplying salad leaves to London markets and restaurants,” added Whately.

“GrowUp is one of the UK’s most exciting and innovative vertical farming operations, experiencing nearly 800% sales increase year over year. Their ability to quickly earn the trust of the UK’s largest retailers shows the appeal of their product lines, the strength of their team, and their ability to meet rising consumer demand for healthy, locally grown food,” said Generate Capital’s CEO and Co-founder Scott Jacobs. “We look forward to working with them to keep accelerating the decarbonisation of the food system by providing nutritious, affordable and sustainable greens to UK consumers and food manufacturers.”

“Since our first investment in 2021, GrowUp’s unique approach has demonstrated that producing superior, sustainable leafy greens at scale and at competitive pricing is possible, unlocking the potential to capture significant market share in the UK salad market,” added Eduardo Clemente, a Managing Director at Generate Capital. “In less than a year from starting operations at industrial scale, GrowUp’s success in securing significant interest and volumes from some of the UK largest retailers is a testament to their value proposition.”

About GrowUp Farms

GrowUp Farms is a purpose-led, award-winning vertical farming business and certified B Corp. It was founded by Kate Hofman and Tom Webster in 2013 in a small unit in London where they created a controlled environment to grow salad leaves that they supplied to Borough Market and London restaurants.

Fast forward 11 years and over £100 million investment, GrowUp has taken a five-acre brownfield site and has created a vertical farm in Kent growing salad leaves 365 days a year. The farm uses state-of-the-art technology and 100% renewable energy from the co-located bioenergy plant to create the ideal environment for their leaves to thrive, ensuring they receive the optimal balance of water, light and nutrients.

Once the Kent farm is fully operational, the site will produce 1.4 million bags of salad per week. GrowUp was the first vertical farm to introduce a branded salad into a supermarket chain in the UK with the launch of Fresh Leaf Co. in Iceland stores across the country in February of 2023 and SPAR in February 2024. The Unbeleafable range launched in Tesco in July 2023. Both brands feature different collections of leaves that are ready-to-eat, fresher and long lasting.

For more information, please visit growupfarms.co.uk.

About Generate Capital

Generate Capital is a leading sustainable investment and operating platform driving the infrastructure transition. Generate aims to provide the capital and help that developers, businesses, cities and communities need to accelerate cost savings, resilience and decarbonization. Since 2014, Generate has invested in and operated sustainable assets across six sectors: power, mobility, waste, green digital, water and agriculture, and industrial decarbonization. With more than $10 billion raised since inception, 50+ technology and development partnerships and more than 2,000 assets globally, Generate’s one-stop-shop offers proof, not promises that sustainability pays. For more information, please visit www.generatecapital.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240717534198/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye